Maria Cristina Riascos

Dr. Maria Cristina Riascos

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
MRMaria Cristina Riascos
Maria Cristina Riascos
AHAnh Huynh
Anh Huynh
WFWilliam Faquin
William Faquin
VNVania Nosé
Vania Nosé
Mutations in DICER1, a gene involved in RNA interference, have been associated with a wide range of multi-organ neoplastic and non-neoplastic conditions. Historically known for its association with pleuropulmonary blastoma, DICER1 syndrome has received more attention due to the association with newly discovered diseases and tumors. Recent studies evaluating DICER1 mutations and DICER1-driven thyroid disease in both pediatric and adult thyroid nodules revealed thyroid disease as the most common manifestation of DICER1 mutations. This study undertakes a comprehensive investigation into DICER1 mutations, focusing on their role in thyroid diseases. Specific attention was given to thyroid follicular nodular disease and differentiated thyroid carcinomas in infancy as highly indicative of germline DICER1 mutation or DICER1 syndrome. Additionally, poorly differentiated thyroid carcinoma and thyroblastoma were identified as potential indicators of somatic DICER1 mutations. Recognizing these manifestations should prompt clinicians to expedite genetic evaluation for this neoplastic syndrome and classify these patients as high risk for additional multi-organ malignancies. This study comprehensively synthesizes the current knowledge surrounding this genetically associated entity, providing intricate details on histologic findings to facilitate its diagnosis.

13 January 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
JLJessica Limberg
Jessica Limberg
CECaitlin E. Egan
Caitlin E. Egan
KGKatherine Gray
Katherine Gray
MSMandeep Singh
Mandeep Singh
ZLZachary Loewenstein
Zachary Loewenstein
IMIrene M. Min
Irene M. Min
A subset of thyroid cancers, recurrent differentiated thyroid cancers and anaplastic thyroid cancer (ATC), are difficult to treat by thyroidectomy and systemic therapy. A common mutation in thyroid cancer, BRAFV600E, has targetable treatment options; however, the results have been disappointing in thyroid cancers compared with BRAFV600E melanoma, as thyroid cancers quickly become resistant to BRAFV600E inhibitor (BRAFi). Here, we studied the molecular pathway that is induced in BRAFV600E thyroid cancer cells and patient-derived tumor samples in response to BRAFi, vemurafenib, using RNA-sequencing and molecular analysis. Both inducible response to BRAFi and acquired BRAFi resistance in BRAFV600E thyroid cancer cells showed significant activation of the JAK/STAT pathway. Functional analyses revealed that the combination of BRAFi and inhibitors of JAK/STAT pathway controlled BRAFV600E thyroid cancer cell growth. The Cancer Genome Atlas data analysis demonstrated that potent activation of the JAK/STAT signaling was associated with shorter recurrence rate in patients with differentiated thyroid cancer. Analysis of tumor RNA expression in patients with poorly differentiated thyroid cancer and ATC also support that enhanced activity of JAK/STAT signaling pathway is correlated with worse prognosis. Our study demonstrates that JAK/STAT pathway is activated as BRAFV600E thyroid cancer cells develop resistance to BRAFi and that this pathway is a potential target for anticancer activity and to overcome drug resistance that commonly develops to treatment with BRAFi in thyroid cancer. Implications: Dual inhibition of BRAF and JAK/STAT signaling pathway is a potential therapeutic treatment for anticancer activity and to overcome drug resistance to BRAFi in thyroid cancer.

8 June 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
IMIrene M. Min
Irene M. Min
YYYanping Yang
Yanping Yang
DSDessislava Stefanova
Dessislava Stefanova
YVYogindra Vedvyas
Yogindra Vedvyas
DBDiella S. Babu
Diella S. Babu
MJMoonsoo Jin
Moonsoo Jin
Engineered T-cell therapies, such as chimeric antigen receptor (CAR)– and T-cell receptor (TCR)–based approaches, have transformed outcomes in hematologic malignancies, yet their efficacy in solid tumors remains limited by tumor antigen escape, immunosuppressive microenvironments, and insufficient activation of CAR or TCR signaling. To overcome these barriers, we developed an intercellular adhesion molecule 1 (ICAM1)–specific chimeric costimulatory receptor (ICCR) engineered for expression in T cells to augment their activation. ICAM1 is broadly expressed across solid tumors and is further upregulated by IFNγ released during early T-cell engagement, creating a feed-forward loop that reinforces tumor recognition. ICCR engagement with ICAM1 triggered NF-κB signaling independently of TCR–peptide (p)/MHC engagement; however, full T-cell activation and cytotoxic function remained dependent on intact TCR signaling. In primary T cells, ICCR increased proliferation, cytokine production, and cytotoxicity, resulting in improved tumor control in two anaplastic thyroid cancer xenograft models treated with allogeneic or autologous ICCR-T cells. Mechanistically, ICCR strengthened tumor cell engagement, promoted selection and expansion of tumor-specific TCR clonotypes, and amplified downstream signaling pathways. These findings identify ICCR as a strategy that leverages an immune synapse–mimetic mechanism to enhance the function of low-activity tumor-specific TCRs and improve T-cell responses in solid tumor microenvironments.

10 June 2026 in Advances in Anatomic Pathology
Verified
Journal Article
Closed access
MRMaria Cristina Riascos
Maria Cristina Riascos
VNVania Nosé
Vania Nosé
DICER1 syndrome is an autosomal dominant tumor predisposition disorder caused by pathogenic variants in the microRNA-processing gene DICER1 . Since its initial recognition in families with pleuropulmonary blastoma, the phenotypic spectrum has expanded to encompass a wide array of benign and malignant neoplasms—including thyroid follicular nodular disease, Sertoli-Leydig cell tumor, cystic nephroma, pituitary blastoma, and embryonal rhabdomyosarcoma of the cervix—often presenting in childhood or early adulthood. This updated review synthesizes current knowledge of DICER1 biology, the historical evolution of the syndrome, the distinctive clinicopathologic features of associated tumors, provides a practical diagnostic algorithm to guide pathologists in recognizing sentinel lesions and initiating germline testing, and recent advances in the study of this syndrome and the DICER1 gene. By integrating molecular mechanisms with evolving clinical practice, this article aims to equip diagnostic pathologists and multidisciplinary teams with diagnostic tools and correlations for the detection and management of DICER1 syndrome.

3 April 2023
Verified
Other
Open access
JLJessica Limberg
Jessica Limberg
CECaitlin E. Egan
Caitlin E. Egan
KGKatherine Gray
Katherine Gray
MSMandeep Singh
Mandeep Singh
ZLZachary Loewenstein
Zachary Loewenstein
IMIrene M. Min
Irene M. Min
S1. BRAFV600E mutation identified in thyroid cancer cell lines analyzed by RNA-seq.S2. STR analysis in thyroid cancer cell lines used in this study.S3. Gene expression of thyroid-specific genes in thyroid cancer cell lines analyzed by RNA-seq.S4. Dose-dependent toxicity of vemurafenib in BRAFV600E thyroidcancer cells.S5. Vemurafenib dose-dependent curves of vemurafenib-resistantBRAFV600E thyroid cancer cells.S6. Vemurafenib induces apoptosis in 8505C cells.S7. Predicted activators and inhibitors in Vem-resistant BRAF mutant thyroid cancer cells.

1 May 2023
Verified
Other
Open access
JLJessica Limberg
Jessica Limberg
CECaitlin E. Egan
Caitlin E. Egan
KGKatherine Gray
Katherine Gray
MSMandeep Singh
Mandeep Singh
ZLZachary Loewenstein
Zachary Loewenstein
IMIrene M. Min
Irene M. Min
Supplementary Table 1. Gene expression changes in 8505C after vemurafenib treatment.Supplementary Table 2. Gene expression changes in WRO after vemurafenib treatment.Supplementary Table 3. Gene expression changes in 8505C -Vem-Res 1 relative to parental 8505C.Supplementary Table 4. Gene expression changes in WRO -Vem-Res 6 relative to parental WRO.Supplementary Table 5. Clinical features of thyroid tumors used in Fig. 5.